GVR Report cover Biologics Market Size, Share & Trends Report

Biologics Market Size, Share & Trends Analysis Report By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi), By Disease Category, By Manufacturing, And Segment Forecasts, 2018 - 2025

  • Published Date: Mar, 2017
  • Base Year for Estimate: 2016
  • Report ID: GVR-1-68038-700-1
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 185

Industry Insights

The global biologics market size was valued at USD 276.6 billion in 2015. These products represent cutting-edge research and also enable the latest scientific discoveries. Such discoveries can be translated into novel therapies that provide new treatment options for patients.

Moreover, an increased understanding of the genetic and molecular basis of disease has opened up the development of a range of targeted treatments. For instance, recombinant proteins aid the immune system in the identification and binding of foreign substances.

U.S. Biologics market share, by disease category, 2014 - 2025 (USD Billion)

U.S. Biologics market

Owing to the fact that small molecule drug R&D productivity is declining, biologics are expected to register lucrative growth in the coming years. Pharmaceutical companies are focusing on the development of several biopharmaceutical products in order to maintain the market position.

Improving efficacy from oral products for rheumatoid arthritis and Crohn’s disease is anticipated to pull more moderate patients to the novel and branded treatments. In addition, novel molecules provide options for treatment-experienced patients and often show superior safety and efficacy.

Advancements pertaining to the development of manufacturing capabilities are projected to boost biopharmaceutical production capacity. These advancements also include the use of single-use systems in the manufacture and processing of biopharmaceuticals.

Furthermore, scientists are engaged in the investigation of species and expression systems that can be more productive. The development of reagents and cell lines that enhance the productivity of the biological products is anticipated to fuel revenue generation.

Source Insights

On the basis of the source used for the manufacturing of these biopharmaceuticals, they are categorized into mainly microbial, mammalian, with an addition of some other sources including transgenic models, avian, insect, and transgenic animals.

Microbial expression systems registered the largest revenue generation due to a substantial number of drugs generated by using these products. Microbial expression systems typically cover Escherichia Coli and yeast.

Products developed through these expression systems include recombinant insulin, platelet-derived growth factor, granulocyte-macrophage colony-stimulating factor, and recombinant interferon. Johnson & Johnson, Novartis, and Genentech are the companies implementing the usage of microbial systems.

Product Insights

Monoclonal antibodies (MABs) dominated the market with the largest revenue share due to higher usage of this category of drugs in different therapeutic areas. MABs allow targeting of unhealthy cells without harming the healthy cells.

Moreover, these drugs are particularly useful in cancer management, treatment of autoimmune diseases, including rheumatoid arthritis. Vaccines are anticipated to witness the fastest growth in the coming years owing to usage as a preventative tool in infectious diseases.

The development of a virus-based therapeutic vaccine is in the process of development for melanoma treatment. This is a genetically-modified product for in tumor cells and expresses a gene for an immune-stimulating protein.

Manufacturing Insights

Manufacturing is a part of the major steps of biologics production and comprises of a significant share of the biologics market. Mode of manufacturing is an important aspect to be considered, as it represents the outsourcing and in-house activities of the sector.

Companies are opting to manufacture than to purchase an entity or outsource the services. This has led to the larger share of in-house manufacturing for biologics. Companies are engaged in investing on own bioprocessing capabilities.

There are investments done by the CMOs for increasing the commercial biopharmaceutical manufacturing capacity. But, the value of the outsourcing contracts is comparatively lower than for the overall market and would be unable to drive sector growth as it does in the pharmaceutical market.

Disease Category Insights

Oncology accounted for the largest share as a consequence of the rising incidence of cancer coupled with the presence of different R&D projects. These projects include gene therapies and antisense therapies for cancer eradication.

Furthermore, oncology is anticipated to maintain its dominance over the forecast period. Drivers for the projected growth include the rising adoption of products in order to reduce the series of adverse events associated with the usage of cancer chemotherapy.

Biologics market, by region, 2015 (USD Billion)

Biologics market

Regional Insights

North America dominated with respect to revenue generation owing to the presence of significant established participants in this region. Moreover, higher demand for the products for the treatment of diseases is attributive for larger revenue share.

In addition, U.S. pharmaceutical companies account for 80% of the world’s R&D in healthcare biotechnology. The aforementioned factor is driving the market in North America.

There has been a spout of heavy investments by the Asian contract manufacturers in order to grab the share in the capital intensive market. Companies such as Samsung Biologics and Wuxi Biologics are anticipated to drive growth in Asia.

Competitive Insights

Major entities operating in this market include Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion, Addgene, Amgen, Abbvie Inc., Sanofi, Pfizer Inc., Merck & Co. Inc, Novo Nordisk A/S, and Johnson & Johnson Services Inc.

The pharma-biotech market involves huge capital investment and is research-intensive in nature. This pronounces the innovator companies to safeguard their intellectual property rights through patenting in target markets.

Companies are embracing the trend of developing delivery devices in order to gain a competitive edge. A proactive approach to delivery technologies is poised to beat the expected growth of biosimilars and bio betters. 

Report Scope

Report Attribute


Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Billion and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa.

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the global biologics market report on the basis of source, product, disease category, manufacturing, and region:

  • Source Outlook (Revenue, USD Billion; 2014 2025)

    • Microbial

    • Mammalian

    • Others

  • Product Outlook (Revenue, USD Billion; 2014 - 2025)

    • Monoclonal Antibodies

      • MABs by application

        • Diagnostic

          • Biochemical Analysis

          • Diagnostic Imaging

        • Therapeutic

          • Direct MAB Agents

          • Targeting MAB Agents

        • Protein Purification

        • Others

      • MABs by type

        • Murine

        • Chimeric

        • Humanized

        • Human

        • Others

    • Vaccines

    • Recombinant Proteins

    • Antisense, RNAi, & Molecular Therapy

    • Others

  • Disease Category Outlook (Revenue, USD Billion; 2014 - 2025)

    • Oncology

      • By Product

        • MABs

        • Vaccines

        • Recombinant Proteins

        • Antisense, RNAi, & Molecular Therapy

        • Others (Certain products under trials related to blood products etc)

    • Infectious Diseases

      • By Product

        • Vaccines

        • MABs

        • Antisense, RNAi, & Molecular Therapy

        • Recombinant Proteins

        • Others

    • Immunological Disorders

    • Cardiovascular Disorders

    • Hematological Disorders

    • Others

  • Biologics Manufacturing Outlook (Revenue, USD Billion; 2014 - 2025)

    • Outsourced

    • In-house

  • Regional Outlook (Revenue, USD Billion; 2013 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

    • Middle East and Africa (MEA)

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.